Tracy Ayers1, Adriana Lopez2, Adria Lee3, Anita Kambhampati3, W Allan Nix2, Elizabeth Henderson2, Shannon Rogers2, William C Weldon2, M Steven Oberste2, James Sejvar4, Sarah E Hopkins5, Mark A Pallansch2, Janell A Routh2, Manisha Patel6. 1. Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia; and. 2. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases. 3. IHRC Inc. contracting agency to the Division of Viral Diseases. 4. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, and. 5. Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 6. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, dvn4@cdc.gov.
Abstract
BACKGROUND: Acute flaccid myelitis (AFM) is a neurologic condition characterized by flaccid limb weakness. After a large number of reports of AFM in 2014, the Centers for Disease Control and Prevention began standardized surveillance in the United States to characterize the disease burden and explore potential etiologies and epidemiologic associations. METHODS: Persons meeting the clinical case criteria of acute flaccid limb weakness from January 1, 2015, through December 31, 2017, were classified as confirmed (spinal cord gray matter lesions on MRI) or probable (white blood cell count >5 cells per mm3 in cerebrospinal fluid [CSF]). We describe clinical, radiologic, laboratory, and epidemiologic findings of pediatric patients (age ≤21 years) confirmed with AFM. RESULTS: Of 305 children reported from 43 states, 193 were confirmed and 25 were probable. Of confirmed patients, 61% were male, with a median age of 6 years (range: 3 months to 21 years; interquartile range: 3 to 10 years). An antecedent respiratory or febrile illness was reported in 79% with a median of 5 days (interquartile range: 2 to 7 days) before limb weakness. Among 153 sterile-site specimens (CSF and serum) submitted to the Centers for Disease Control and Prevention, coxsackievirus A16 was detected in CSF and serum of one case patient and enterovirus D68 was detected in serum of another. Of 167 nonsterile site (respiratory and stool) specimens, 28% tested positive for enterovirus or rhinovirus. CONCLUSIONS: AFM surveillance data suggest a viral etiology, including enteroviruses. Further study is ongoing to better characterize the etiology, pathogenesis, and risk factors of this rare condition.
BACKGROUND: Acute flaccid myelitis (AFM) is a neurologic condition characterized by flaccid limb weakness. After a large number of reports of AFM in 2014, the Centers for Disease Control and Prevention began standardized surveillance in the United States to characterize the disease burden and explore potential etiologies and epidemiologic associations. METHODS:Persons meeting the clinical case criteria of acute flaccid limb weakness from January 1, 2015, through December 31, 2017, were classified as confirmed (spinal cord gray matter lesions on MRI) or probable (white blood cell count >5 cells per mm3 in cerebrospinal fluid [CSF]). We describe clinical, radiologic, laboratory, and epidemiologic findings of pediatric patients (age ≤21 years) confirmed with AFM. RESULTS: Of 305 children reported from 43 states, 193 were confirmed and 25 were probable. Of confirmed patients, 61% were male, with a median age of 6 years (range: 3 months to 21 years; interquartile range: 3 to 10 years). An antecedent respiratory or febrile illness was reported in 79% with a median of 5 days (interquartile range: 2 to 7 days) before limb weakness. Among 153 sterile-site specimens (CSF and serum) submitted to the Centers for Disease Control and Prevention, coxsackievirus A16 was detected in CSF and serum of one case patient and enterovirus D68 was detected in serum of another. Of 167 nonsterile site (respiratory and stool) specimens, 28% tested positive for enterovirus or rhinovirus. CONCLUSIONS: AFM surveillance data suggest a viral etiology, including enteroviruses. Further study is ongoing to better characterize the etiology, pathogenesis, and risk factors of this rare condition.
Authors: Nicholas M Kiulia; Raul Gonzalez; Hannah Thompson; Tiong Gim Aw; Joan B Rose Journal: Food Environ Virol Date: 2021-02-16 Impact factor: 2.778
Authors: Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo Journal: Lancet Date: 2020-12-23 Impact factor: 79.321
Authors: C O Heise; A J de Oliveira; T Bhering; R S Martins; H Sterman-Neto; L Foroni; M G Siqueira Journal: Childs Nerv Syst Date: 2020-07-14 Impact factor: 1.532
Authors: Benjamin Greenberg; Patricia Plumb; Gary Cutter; Janet Dean; Allen Desena; Sarah Hopkins; Chitra Krishnan; Carlos Pardo; Albert Recio; Teri Schreiner; E Ann Yeh; Morgan McCreary Journal: BMJ Neurol Open Date: 2021-05-19
Authors: William C Weldon; Kun Zhao; Heather A Jost; Kimbell Hetzler; Jessica Ciomperlik-Patton; Jennifer L Konopka-Anstadt; M Steven Oberste Journal: J Clin Virol Date: 2020-08-18 Impact factor: 14.481
Authors: Nilay McLaren; Adriana Lopez; Sarah Kidd; John X Zhang; W Allan Nix; Ruth Link-Gelles; Adria Lee; Janell A Routh Journal: Emerg Infect Dis Date: 2020-02 Impact factor: 6.883
Authors: Pranav N M Shah; David J Filman; Krishanthi S Karunatilaka; Emma L Hesketh; Elisabetta Groppelli; Mike Strauss; James M Hogle Journal: PLoS Pathog Date: 2020-09-30 Impact factor: 7.464